11 September 2012, London: College Hill Life Sciences clients' are well represented in the list of finalists for the 2012 Scrip awards, with Mesoblast, Prosensa and Roche and all making it to the shortlist, following the nomination entries prepared and submitted by College Hill.
Prosensa Therapeutics, which was EuropaBio SME Biotech company of the year in 2011, has again been shortlisted for the coveted Biotechnology Company of the Year Award as well as Financing Deal of the Year. A Dutch biopharmaceutical company which closed a €23m series C financing in January 2012, Prosensa is focusing on rare diseases with an unmet medical need - particularly Duchenne Muscular Dystrophy for which it has a exon-skipping RNA drug in Phase III development, partnered with GSK.
Competition for Biotechnology Company of the Year will be tough, as Mesoblast, the Australian-based regenerative medicinces company, has also been shortlisted for this Award as well as in the new award category of Clinical Advance of the Year for its Phase II trial of stem cell therapy Revascor in congestive heart failure.
Roche was yet again shortlisted in the Best Partnership Alliance category, this year for its deal with PTC Therapeutics and the SMA Foundation to develop drugs for spinal muscular atrophy.
Commenting on the awards Sue Charles, Managing Partner said: "We encourage our clients to put themselves forwards for the prestigious Scrip Awards and are delighted to support them in their entry nominations. It is exciting that our clients are up for a total of five awards this year and we wish them and all other finalists the best of luck - the quality of companies shortlisted is very high, so competition will be fierce."
The winners will be announced at the glittering black tie ceremony to be held at London's Lancaster Hotel on 28 November, where College Hill will be hosting a table. For further information about the Awards ceremony please click here
For further information:
Sue Charles, Managing Partner
UK: +44 (0)20 7457 2020/ +44 (0)7968 726 585
Australia: +61 (0)457 924 218